Suzanne V Arnold1, Yiran Zhang2, Suzanne J Baron3, Thomas C McAndrew2, Maria C Alu2, Susheel K Kodali2, Samir Kapadia4, Vinod H Thourani5, D Craig Miller6, Michael J Mack7, Martin B Leon2, David J Cohen3. 1. Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri. Electronic address: suz.v.arnold@gmail.com. 2. Columbia-Presbyterian Hospital, New York, New York. 3. Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri. 4. Cleveland Clinic Foundation, Cleveland, Ohio. 5. Medstar Washington Hospital Center/Georgetown University, Washington, District of Columbia. 6. Stanford University Medical School, Stanford, California. 7. Baylor Scott and White Health, Plano, Texas.
Abstract
OBJECTIVES: The aim of this study was to examine the independent association of short-term complications of transcatheter aortic valve replacement (TAVR) with survival and quality of life at 1 year. BACKGROUND: Prior studies have examined the mortality and cost implications of various complications of TAVR. However, many of these complications may primarily affect patients' quality of life after TAVR, which has not been previously studied. METHODS: Among patients at intermediate or high surgical risk who underwent TAVR as part of the PARTNER (Placement of Aortic Transcatheter Valve) 2 studies and survived 30 days, the association between complications within the 30 days after TAVR and mortality and quality of life at 1 year was examined. Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the Short-Form 12. Complications assessed included major and minor stroke, life-threatening and major bleeding, vascular injury, stage 3 acute kidney injury, new pacemaker implantation, and mild and moderate or severe paravalvular leak (PVL). Multivariable models that included all complications as well as baseline clinical factors were used to examine the independent association of each complication with outcomes. RESULTS: Among 3,763 TAVR patients, major stroke and stage 3 acute kidney injury were associated with markedly increased risk for 1-year mortality, with adjusted hazard ratios of 5.4 (95% confidence interval [CI]: 3.1 to 9.5) and 4.9 (95% CI: 2.7 to 8.8), respectively, as well as poorer quality of life among survivors (reductions in 1-year Kansas City Cardiomyopathy Questionnaire overall summary score of 15.1 points [95% CI: 24.8 to 5.3 points] and 14.7 points [95% CI: 25.6 to 3.8 points], respectively). Moderate or severe PVL, life-threatening bleeding, and major bleeding were each associated with a more modest increase in mortality and decrement in quality of life, whereas mild PVL was associated with a small decrease in quality of life. After adjusting for baseline characteristics and other complications, need for a new pacemaker, minor stroke, and vascular injury were not independently associated with poor outcomes. CONCLUSIONS: Among patients undergoing TAVR, similar events are associated with increased mortality and impaired quality of life at 1 year. These results suggest that despite considerable progress, efforts to further reduce stroke, acute kidney injury, bleeding, and moderate or severe PVL are likely to yield important clinical benefits and remain key targets for device iteration and procedural improvement.
OBJECTIVES: The aim of this study was to examine the independent association of short-term complications of transcatheter aortic valve replacement (TAVR) with survival and quality of life at 1 year. BACKGROUND: Prior studies have examined the mortality and cost implications of various complications of TAVR. However, many of these complications may primarily affect patients' quality of life after TAVR, which has not been previously studied. METHODS: Among patients at intermediate or high surgical risk who underwent TAVR as part of the PARTNER (Placement of Aortic Transcatheter Valve) 2 studies and survived 30 days, the association between complications within the 30 days after TAVR and mortality and quality of life at 1 year was examined. Quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the Short-Form 12. Complications assessed included major and minor stroke, life-threatening and major bleeding, vascular injury, stage 3 acute kidney injury, new pacemaker implantation, and mild and moderate or severe paravalvular leak (PVL). Multivariable models that included all complications as well as baseline clinical factors were used to examine the independent association of each complication with outcomes. RESULTS: Among 3,763 TAVR patients, major stroke and stage 3 acute kidney injury were associated with markedly increased risk for 1-year mortality, with adjusted hazard ratios of 5.4 (95% confidence interval [CI]: 3.1 to 9.5) and 4.9 (95% CI: 2.7 to 8.8), respectively, as well as poorer quality of life among survivors (reductions in 1-year Kansas City Cardiomyopathy Questionnaire overall summary score of 15.1 points [95% CI: 24.8 to 5.3 points] and 14.7 points [95% CI: 25.6 to 3.8 points], respectively). Moderate or severe PVL, life-threatening bleeding, and major bleeding were each associated with a more modest increase in mortality and decrement in quality of life, whereas mild PVL was associated with a small decrease in quality of life. After adjusting for baseline characteristics and other complications, need for a new pacemaker, minor stroke, and vascular injury were not independently associated with poor outcomes. CONCLUSIONS: Among patients undergoing TAVR, similar events are associated with increased mortality and impaired quality of life at 1 year. These results suggest that despite considerable progress, efforts to further reduce stroke, acute kidney injury, bleeding, and moderate or severe PVL are likely to yield important clinical benefits and remain key targets for device iteration and procedural improvement.
Authors: Matthew R Reynolds; Elizabeth A Magnuson; Yang Lei; Martin B Leon; Craig R Smith; Lars G Svensson; John G Webb; Vasilis C Babaliaros; Bruce S Bowers; William F Fearon; Howard C Herrmann; Samir Kapadia; Susheel K Kodali; Raj R Makkar; Augusto D Pichard; David J Cohen Journal: Circulation Date: 2011-10-03 Impact factor: 29.690
Authors: Michael J Mack; Martin B Leon; Craig R Smith; D Craig Miller; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Pamela S Douglas; William N Anderson; Eugene H Blackstone; Susheel K Kodali; Raj R Makkar; Gregory P Fontana; Samir Kapadia; Joseph Bavaria; Rebecca T Hahn; Vinod H Thourani; Vasilis Babaliaros; Augusto Pichard; Howard C Herrmann; David L Brown; Mathew Williams; Jodi Akin; Michael J Davidson; Lars G Svensson Journal: Lancet Date: 2015-03-15 Impact factor: 79.321
Authors: Suzanne V Arnold; Yang Lei; Matthew R Reynolds; Elizabeth A Magnuson; Rakesh M Suri; E Murat Tuzcu; John L Petersen; Pamela S Douglas; Lars G Svensson; Hemal Gada; Vinod H Thourani; Susheel K Kodali; Michael J Mack; Martin B Leon; David J Cohen Journal: Circ Cardiovasc Interv Date: 2014-10-21 Impact factor: 6.546
Authors: Michael J Reardon; David H Adams; Neal S Kleiman; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Joon Sup Lee; James B Hermiller; Stan Chetcuti; John Heiser; William Merhi; George L Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; Brijeshwar Maini; Mubashir Mumtaz; John V Conte; Jon R Resar; Vicken Aharonian; Thomas Pfeffer; Jae K Oh; Hongyan Qiao; Jeffrey J Popma Journal: J Am Coll Cardiol Date: 2015-06-05 Impact factor: 24.094
Authors: A Pieter Kappetein; Stuart J Head; Philippe Généreux; Nicolo Piazza; Nicolas M van Mieghem; Eugene H Blackstone; Thomas G Brott; David J Cohen; Donald E Cutlip; Gerrit-Anne van Es; Rebecca T Hahn; Ajay J Kirtane; Mitchell W Krucoff; Susheel Kodali; Michael J Mack; Roxana Mehran; Josep Rodés-Cabau; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys; Martin B Leon Journal: J Am Coll Cardiol Date: 2012-10-09 Impact factor: 24.094
Authors: Philippe Pibarot; Rebecca T Hahn; Neil J Weissman; Marie Arsenault; Jonathan Beaudoin; Mathieu Bernier; Abdellaziz Dahou; Omar K Khalique; Federico M Asch; Oumhani Toubal; Jonathon Leipsic; Philipp Blanke; Feifan Zhang; Rupa Parvataneni; Maria Alu; Howard Herrmann; Raj Makkar; Michael Mack; Richard Smalling; Martin Leon; Vinod H Thourani; Susheel Kodali Journal: JAMA Cardiol Date: 2017-11-01 Impact factor: 14.676
Authors: Frederick L Grover; Sreekanth Vemulapalli; John D Carroll; Fred H Edwards; Michael J Mack; Vinod H Thourani; Ralph G Brindis; David M Shahian; Carlos E Ruiz; Jeffrey P Jacobs; George Hanzel; Joseph E Bavaria; E Murat Tuzcu; Eric D Peterson; Susan Fitzgerald; Matina Kourtis; Joan Michaels; Barbara Christensen; William F Seward; Kathleen Hewitt; David R Holmes Journal: J Am Coll Cardiol Date: 2016-12-09 Impact factor: 24.094
Authors: Christian Frerker; Tobias Schmidt; Max M Meertens; Sascha Macherey; Sebastiaan Asselberghs; Samuel Lee; Jan Hendrik Schipper; Barend Mees; Ingo Eitel; Stephan Baldus Journal: Clin Res Cardiol Date: 2022-03-17 Impact factor: 6.138
Authors: Guillaume Marquis-Gravel; Amanda Stebbins; Andrzej S Kosinski; Morgan L Cox; J Kevin Harrison; G Chad Hughes; Vinod H Thourani; Thomas G Gleason; Ajay J Kirtane; John D Carroll; Michael J Mack; Sreekanth Vemulapalli Journal: JAMA Cardiol Date: 2020-09-01 Impact factor: 14.676
Authors: Diego H González-Bravo; Pedro Colón-Hernández; Melanie Quintana-Serrano; Sergio Alegre-Boschetti; Juan Vázquez-Fuster; José J Acevedo-Valles; Eric Avilés-Rivera Journal: Case Rep Cardiol Date: 2022-04-05
Authors: Sandra B Lauck; Maggie Yu; Lillian Ding; Sean Hardiman; Daniel Wong; Janarthanan Sathananthan; Jian Ye; Albert Chan; Steven Hodge; Simon Robinson; David A Wood; John G Webb Journal: CJC Open Date: 2021-04-24
Authors: Amgad Mentias; Marwan Saad; Milind Y Desai; Phillip A Horwitz; James D Rossen; Sidakpal Panaich; Ayman Elbadawi; Abdul Qazi; Paul Sorajja; Hani Jneid; Samir Kapadia; Barry London; Mary S Vaughan Sarrazin Journal: J Am Heart Assoc Date: 2019-10-31 Impact factor: 5.501